Fiche société
Johns Hopkins University
Traitements, essais et publications liés.
Traitements51programmes
Essais33liés
Publications28liées
SourceDBlocale
Traitements
51| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| [11C]CPPC PET ligandDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1/2 | À vérifier | À vérifier | |
| Active tDCS (tDCS) on DLPFCThe primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with Primary Progressive Aphasia (PPA), mild cognitive impairment (MCI), or dementia. In this study, investigators will use transcranial direct current stimulation (tDCS) to stimulate the left dorsolateral prefrontal cortex (DLPFC). Previous studies have demonstrated that tDCS over the DLPFC led to improvements in attention deficit caused by stroke, Parkinson's Disease, and major depression as well as language deficits caused by neurodegenerative conditions such as primary progressive aphasia or mild cognitive impairment. The investigators seek to expand on this literature by investigating how anodal tDCS paired with and without cognitive training will impact executive functioning in PPA with Frontotemporal Dementia or Alzheimer's Disease pathology and Mild Cognitive Impairment/Alzheimer's Disease (e.g. shifting, updating, monitoring, and manipulation). | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| AFSW Guided DOACREACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk. | Accident vasculaire cérébral | Phase 3 | À vérifier | United States | À vérifier |
| AGB101This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams. | Parkinson | Phase 2 | Traitement symptomatique | United States | À vérifier |
| ALIGN: Aligning Medications With What Matters Most (Demonstration)The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners. The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of the person's goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored de-prescribing recommendations designed to be useful and actionable for the PCP. The investigators will compare the intervention group with the waitlist control group to see if there is a difference in the primary outcome, the proportion of patients who deprescribe at least one medication by 3 months. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Anodal Transcranial direct current stimulationThis research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities in individuals with multiple sclerosis (MS) or encephalitis. Participants will be asked to come in daily for two full weeks during which time participants will undergo cognitive testing and Magnetic Resonance Imaging (MRI) brain scans. In this research, a very weak electrical current is administered to the surface of the scalp while participants complete cognitive tasks. The investigators' aim is to find out whether tDCS will improve task performance in adults with multiple sclerosis or encephalitis. | Migraine, SEP | NA | À vérifier | United States | À vérifier |
| Atorvastatin 10mgKetogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol. | Épilepsie | Phase 1/2 | À vérifier | United States | À vérifier |
| BelimumabThis study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865) | Lupus, Myasthénie, SEP | Phase 2 | À vérifier | United States | À vérifier |
| Continued OcrelizumabMultiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults. Depleting B cells from the circulation with an anti-cluster of differentiation (CD) 20 antibodies has proven to be an effective strategy in reducing relapses and disability in patients with the relapsing-remitting disease. However, continuous and long-term depletion of B-cells can result in reduced immunoglobulin levels, immunosuppression, and an increased tendency for severe infections and perhaps, even malignancy. Blocking B-cell Activating Factor (BAFF) is effective for the treatment of several autoimmune disorders. Belimumab, a BAFF blocking antibody, has been approved by the Food and Drug Administration for the treatment of systemic lupus erythematosus. Belimumab has been shown to have immunomodulatory properties, without resulting in overt immunosuppression. The investigators hypothesize that belimumab, given to patients who received a short course of treatment with B-cell depleting antibody (ocrelizumab), will be safe and equally effective in reducing MS disease activity (as compared to patients receiving continuous treatment with ocrelizumab); while resulting in less immunosuppression, as measured by antibody response to pneumococcal vaccination. Currently, available treatment strategies in relapsing MS sacrifice higher efficacy for long-term safety or vice versa. The proposed strategy in this application combines the long-term safety and high efficacy to treat patients with relapsing-remitting multiple sclerosis (RRMS) and, if eventually proven effective, can be adopted in a large proportion of patients with this chronic disease. This is a randomized, open-labeled trial. Forty eligible participants will be randomized 1:1 to either receiving a form of standard of care, ocrelizumab (300 mg two infusions two weeks apart at baseline and then 600 mg as a single infusion every six months) or belimumab (200 mg subcutaneous (SC) weekly for 36 months) plus two courses of ocrelizumab (300 mg two infusions two weeks apart at baseline and 600 mg as a single infusion six months later). Co-primary outcomes of the study include pneumococcal vaccine antibody response, the return of MS disease activity, and proportions of patients with adverse events and serious adverse events. | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
| Continuous DOAC therapyREACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk. | Accident vasculaire cérébral | Phase 3 | À vérifier | United States | À vérifier |
| embolization of middle meningeal arteriesThis study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research. | Migraine | Non applicable | À vérifier | United States | À vérifier |
| Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive DeclineThe goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years. | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| HEARS-NPS deviceThis randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symptoms (NPS), and care partner distress. | Alzheimer | Non applicable | Traitement symptomatique | United States | À vérifier |
| hyaluronidase plus salineShoulder pain is extremely common after stroke and occurs in 30-70% of patients. The pain may begin as early as one week after stroke, although peak onset and severity occurs around four months, and persists into the chronic stage. Chronic post stroke shoulder pain (PSSP) interferes with motor recovery, decreases quality of life, and contributes to depression. PSSP is thought to be caused mainly by damage to the myofascial tissues around the shoulder joint. Interestingly, an MRI study in patients with PSSP showed that the degree of structural damage to the muscles did not correlate with the degree of pain. Thus, the pathophysiology of myofascial dysfunction and pain in PSSP has not been elucidated leading to missed opportunities for early diagnosis and variable success with pain management. The accumulation of hyaluronic acid (HA) in muscle and its fascia can cause myofascial dysfunction. HA is a glycosaminoglycan (GAG) consisting of long-chain polymers of disaccharide units of glucuronic acid and N-acetylglucosamine and is a chief constituent of the extracellular matrix of muscle. In physiologic quantities, HA functions as a lubricant and a viscoelastic shock absorber, enabling force transmission during contraction and stretch. Reduced joint mobility and spasticity result in focal accumulation and alteration of HA in muscle. This can lead to the development of stiff areas and taut bands, dysfunctional gliding of deep fascia and muscle layers, reduced range of motion (ROM), and pain. However, the association of muscle HA accumulation with PSSP has not been established. The investigators have quantified the concentration of HA in muscle using T1rho (T1ρ) MRI and found that T1ρ relaxation time is increased in post stroke shoulder pain and stiffness. Furthermore, dynamic US imaging using shear strain mapping can quantify dysfunctional gliding of muscle that may generate pain during ROM. Myofascial dysfunction can result in non-painful reduction in ROM (latent PSSP), which may become painful due to episodic overuse injury producing greater shear dysfunction (active PSSP). Hence, shear strain mapping may differentiate between latent versus active PSSP. Thus, quantitative Motor Recovery (MR) and US imaging may serve as useful biomarkers to elucidate the pathophysiology of myofascial dysfunction. | Accident vasculaire cérébral | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With EpilepsyThis research is being done to evaluate the short term and long term effects of ketogenic diets on measures of cardiovascular health. Such measures include cholesterol levels, blood pressure, weight, and thickening of the blood vessel wall over time. Adults aged 18 or older who are already on a ketogenic diet for at least 12 months or who are interested in beginning on the modified Atkins diet may join. | Épilepsie | À vérifier | À vérifier | United States | À vérifier |
| INTENT Neural Interface SystemThe goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices. | Accident vasculaire cérébral, Myopathies, Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| LINKED-BP — Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood PressureThe LINKED-BP Program is a patient-centered, multi-level intervention linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo) that links with all Bluetooth-enabled validated blood pressure (BP) devices, support from community health workers (CHWs), and BP measurement training at community health centers serving high-risk adults to prevent stage 2 hypertension (BP ≥ 140/90 mm Hg). The LINKED-BP Program study will recruit a total of 600 adults (30 from each practice) with elevated BP (120-129/\<80 mm Hg) or untreated stage 1 hypertension (130-139/80-89 mm Hg) across 20 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors (HBPM) and will be managed by the patients' primary care clinicians as usual; and (2) the LINKED-BP Program or "intervention arm," which will include training of patients on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. The intervention period for each study participant is 12 months. | Hypertension | Non applicable | À vérifier | United States | À vérifier |
| Migraine and Body CompositionThis research is being done to look at the association between migraine and obesity. | Migraine | À vérifier | À vérifier | United States | À vérifier |
| NLY01The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy). | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
| Radiofrequency AblationThe objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery. | Cancer, Parkinson | Non applicable | À vérifier | United States | À vérifier |
| Short-course OcrelizumabMultiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults. Depleting B cells from the circulation with an anti-cluster of differentiation (CD) 20 antibodies has proven to be an effective strategy in reducing relapses and disability in patients with the relapsing-remitting disease. However, continuous and long-term depletion of B-cells can result in reduced immunoglobulin levels, immunosuppression, and an increased tendency for severe infections and perhaps, even malignancy. Blocking B-cell Activating Factor (BAFF) is effective for the treatment of several autoimmune disorders. Belimumab, a BAFF blocking antibody, has been approved by the Food and Drug Administration for the treatment of systemic lupus erythematosus. Belimumab has been shown to have immunomodulatory properties, without resulting in overt immunosuppression. The investigators hypothesize that belimumab, given to patients who received a short course of treatment with B-cell depleting antibody (ocrelizumab), will be safe and equally effective in reducing MS disease activity (as compared to patients receiving continuous treatment with ocrelizumab); while resulting in less immunosuppression, as measured by antibody response to pneumococcal vaccination. Currently, available treatment strategies in relapsing MS sacrifice higher efficacy for long-term safety or vice versa. The proposed strategy in this application combines the long-term safety and high efficacy to treat patients with relapsing-remitting multiple sclerosis (RRMS) and, if eventually proven effective, can be adopted in a large proportion of patients with this chronic disease. This is a randomized, open-labeled trial. Forty eligible participants will be randomized 1:1 to either receiving a form of standard of care, ocrelizumab (300 mg two infusions two weeks apart at baseline and then 600 mg as a single infusion every six months) or belimumab (200 mg subcutaneous (SC) weekly for 36 months) plus two courses of ocrelizumab (300 mg two infusions two weeks apart at baseline and 600 mg as a single infusion six months later). Co-primary outcomes of the study include pneumococcal vaccine antibody response, the return of MS disease activity, and proportions of patients with adverse events and serious adverse events. | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
| Smartphone Mindfulness Meditation for Patients With Rheumatic DiseasesThis study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease. | Lupus | NA | À vérifier | United States | À vérifier |
| Surgical implantation of CortiCom systemThe CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| Team-based shared decision-makingThe investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only. | Hypertension | Phase 1 | À vérifier | À vérifier | |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis TrialFDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability. | SEP | Non applicable | À vérifier | United States | À vérifier |
| Smartphone Mindfulness Meditation for Patients With Rheumatic DiseasesThis study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease. | Lupus | NA | À vérifier | United States | À vérifier |
| Migraine and Body CompositionThis research is being done to look at the association between migraine and obesity. | Migraine | À vérifier | À vérifier | United States | À vérifier |
| BelimumabThis study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865) | Lupus | Phase 1 | À vérifier | China | À vérifier |
| BelimumabThis study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865) | Myasthénie | Phase 2 | À vérifier | United States, Canada, Germany, Italy | À vérifier |
| embolization of middle meningeal arteriesThis study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research. | Migraine | Non applicable | À vérifier | United States | À vérifier |
| Anodal Transcranial direct current stimulationThis research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities in individuals with multiple sclerosis (MS) or encephalitis. Participants will be asked to come in daily for two full weeks during which time participants will undergo cognitive testing and Magnetic Resonance Imaging (MRI) brain scans. In this research, a very weak electrical current is administered to the surface of the scalp while participants complete cognitive tasks. The investigators' aim is to find out whether tDCS will improve task performance in adults with multiple sclerosis or encephalitis. | Migraine | Non applicable | À vérifier | À vérifier | |
| Team-based shared decision-makingThe investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only. | Hypertension | Phase 1 | À vérifier | À vérifier | |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis TrialFDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability. | SEP | Non applicable | À vérifier | United States | À vérifier |
| ALIGN: Aligning Medications With What Matters Most (Demonstration)The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners. The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of the person's goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored de-prescribing recommendations designed to be useful and actionable for the PCP. The investigators will compare the intervention group with the waitlist control group to see if there is a difference in the primary outcome, the proportion of patients who deprescribe at least one medication by 3 months. | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| INTENT Neural Interface SystemThe goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| LINKED-BP — Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood PressureThe LINKED-BP Program is a patient-centered, multi-level intervention linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo) that links with all Bluetooth-enabled validated blood pressure (BP) devices, support from community health workers (CHWs), and BP measurement training at community health centers serving high-risk adults to prevent stage 2 hypertension (BP ≥ 140/90 mm Hg). The LINKED-BP Program study will recruit a total of 600 adults (30 from each practice) with elevated BP (120-129/\<80 mm Hg) or untreated stage 1 hypertension (130-139/80-89 mm Hg) across 20 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors (HBPM) and will be managed by the patients' primary care clinicians as usual; and (2) the LINKED-BP Program or "intervention arm," which will include training of patients on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. The intervention period for each study participant is 12 months. | Hypertension | Non applicable | À vérifier | United States | À vérifier |
| Radiofrequency AblationThe objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery. | Parkinson | À vérifier | À vérifier | Germany, United Kingdom | À vérifier |
| BelimumabThis study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865) | SEP | Phase 2 | À vérifier | United States | À vérifier |
| Surgical implantation of CortiCom systemThe CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement. | Sclérose latérale amyotrophique | Non applicable | À vérifier | United States | À vérifier |
| [11C]CPPC PET ligandDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1/2 | À vérifier | ||
| AGB101This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams. | Parkinson | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With EpilepsyThis research is being done to evaluate the short term and long term effects of ketogenic diets on measures of cardiovascular health. Such measures include cholesterol levels, blood pressure, weight, and thickening of the blood vessel wall over time. Adults aged 18 or older who are already on a ketogenic diet for at least 12 months or who are interested in beginning on the modified Atkins diet may join. | Épilepsie | À vérifier | À vérifier | United States | À vérifier |
| Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive DeclineThe goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years. | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| Radiofrequency AblationThe objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery. | Cancer | Non applicable | À vérifier | South Korea | À vérifier |
| AFSW Guided DOACREACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk. | Accident vasculaire cérébral | Phase 3 | À vérifier | United States | À vérifier |
| hyaluronidase plus salineShoulder pain is extremely common after stroke and occurs in 30-70% of patients. The pain may begin as early as one week after stroke, although peak onset and severity occurs around four months, and persists into the chronic stage. Chronic post stroke shoulder pain (PSSP) interferes with motor recovery, decreases quality of life, and contributes to depression. PSSP is thought to be caused mainly by damage to the myofascial tissues around the shoulder joint. Interestingly, an MRI study in patients with PSSP showed that the degree of structural damage to the muscles did not correlate with the degree of pain. Thus, the pathophysiology of myofascial dysfunction and pain in PSSP has not been elucidated leading to missed opportunities for early diagnosis and variable success with pain management. The accumulation of hyaluronic acid (HA) in muscle and its fascia can cause myofascial dysfunction. HA is a glycosaminoglycan (GAG) consisting of long-chain polymers of disaccharide units of glucuronic acid and N-acetylglucosamine and is a chief constituent of the extracellular matrix of muscle. In physiologic quantities, HA functions as a lubricant and a viscoelastic shock absorber, enabling force transmission during contraction and stretch. Reduced joint mobility and spasticity result in focal accumulation and alteration of HA in muscle. This can lead to the development of stiff areas and taut bands, dysfunctional gliding of deep fascia and muscle layers, reduced range of motion (ROM), and pain. However, the association of muscle HA accumulation with PSSP has not been established. The investigators have quantified the concentration of HA in muscle using T1rho (T1ρ) MRI and found that T1ρ relaxation time is increased in post stroke shoulder pain and stiffness. Furthermore, dynamic US imaging using shear strain mapping can quantify dysfunctional gliding of muscle that may generate pain during ROM. Myofascial dysfunction can result in non-painful reduction in ROM (latent PSSP), which may become painful due to episodic overuse injury producing greater shear dysfunction (active PSSP). Hence, shear strain mapping may differentiate between latent versus active PSSP. Thus, quantitative Motor Recovery (MR) and US imaging may serve as useful biomarkers to elucidate the pathophysiology of myofascial dysfunction. | Accident vasculaire cérébral | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Active tDCS (tDCS) on DLPFCThe primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with Primary Progressive Aphasia (PPA), mild cognitive impairment (MCI), or dementia. In this study, investigators will use transcranial direct current stimulation (tDCS) to stimulate the left dorsolateral prefrontal cortex (DLPFC). Previous studies have demonstrated that tDCS over the DLPFC led to improvements in attention deficit caused by stroke, Parkinson's Disease, and major depression as well as language deficits caused by neurodegenerative conditions such as primary progressive aphasia or mild cognitive impairment. The investigators seek to expand on this literature by investigating how anodal tDCS paired with and without cognitive training will impact executive functioning in PPA with Frontotemporal Dementia or Alzheimer's Disease pathology and Mild Cognitive Impairment/Alzheimer's Disease (e.g. shifting, updating, monitoring, and manipulation). | Alzheimer | Non applicable | À vérifier | United States | À vérifier |
| Atorvastatin 10mgKetogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol. | Épilepsie | Phase 1/2 | À vérifier | United States | À vérifier |
| NLY01The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy). | SEP | Phase 2 | Immunomodulation | United States | À vérifier |
| HEARS-NPS deviceThis randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symptoms (NPS), and care partner distress. | Alzheimer | Non applicable | Traitement symptomatique | United States | À vérifier |
| Radiofrequency AblationThe objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery. | Cancer | Non applicable | À vérifier | United States | À vérifier |
Essais cliniques
33| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Radiofrequency Ablation | Cancer | Non applicable | NCT05132205 | Radiofrequency Ablation of Papillary Thyroid Microcarcinoma | COMPLETED |
| HEARS-NPS device | Alzheimer | Non applicable | NCT06930560 | HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms | RECRUITING |
| NLY01 | SEP | Phase 2 | NCT07497399 | TAG-MS — Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | RECRUITING |
| Atorvastatin 10mg | Épilepsie | Phase 1/2 | NCT06369571 | Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet | ENROLLING_BY_INVITATION |
| Active tDCS (tDCS) on DLPFC | Alzheimer | Non applicable | NCT05978804 | Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease | TERMINATED |
| hyaluronidase plus saline | Accident vasculaire cérébral | Phase 2 | NCT06718413 | Myofascial Dysfunction in Post Stroke Shoulder Pain | RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| Radiofrequency Ablation | Cancer | Non applicable | NCT05580224 | Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma | UNKNOWN |
| Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline | Alzheimer | À vérifier | NCT05556395 | Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline | RECRUITING |
| Psilocybin | Alzheimer | Phase 1 | NCT04123314 | Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | RECRUITING |
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | Épilepsie | À vérifier | NCT02694094 | Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT04261790 | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis | COMPLETED |
| AGB101 | Parkinson | Phase 2 | NCT05824728 | AGB101 PDP — Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis | ACTIVE_NOT_RECRUITING |
| [11C]CPPC PET ligand | Sclérose latérale amyotrophique | Phase 1/2 | NCT05602142 | Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS | NOT_YET_RECRUITING |
| Surgical implantation of CortiCom system | Sclérose latérale amyotrophique | Non applicable | NCT03567213 | Investigation on the Cortical Communication (CortiCom) System | RECRUITING |
| Belimumab | SEP | Phase 2 | NCT04767698 | Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis | TERMINATED |
| Radiofrequency Ablation | Parkinson | À vérifier | NCT06553625 | Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS | RECRUITING |
| LINKED-BP — Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure | Hypertension | Non applicable | NCT05180045 | LINKED-BP — Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure | COMPLETED |
| INTENT Neural Interface System | Sclérose latérale amyotrophique | Non applicable | NCT07521930 | Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) | RECRUITING |
| ALIGN: Aligning Medications With What Matters Most (Demonstration) | Alzheimer | Non applicable | NCT06335953 | ALIGN: Aligning Medications With What Matters Most (Demonstration) | COMPLETED |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| Team-based shared decision-making | Hypertension | Phase 1 | NCT07662616 | SDM in CKM — Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health | NOT_YET_RECRUITING |
| Anodal Transcranial direct current stimulation | Migraine | Non applicable | NCT01752439 | Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache | UNKNOWN |
| embolization of middle meningeal arteries | Migraine | Non applicable | NCT07223008 | MMAE-Migraine — Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine | RECRUITING |
| Ublituximab | SEP | Phase 4 | NCT07389590 | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | RECRUITING |
| Belimumab | Myasthénie | Phase 2 | NCT01480596 | The Evaluation of Belimumab in Myasthenia Gravis (MG) | COMPLETED |
| Belimumab | Lupus | Phase 1 | NCT05917288 | A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus | COMPLETED |
| Migraine and Body Composition | Migraine | À vérifier | NCT01720862 | Migraine and Body Composition | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT03853746 | Short-term B-cell Depletion in Relapsing Multiple Sclerosis | COMPLETED |
| Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases | Lupus | NA | NCT03937856 | Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases | TERMINATED |
| Ocrelizumab | SEP | À vérifier | NCT03873389 | Ocrelizumab Effects on the Metabolome in MS | COMPLETED |
| Sham Transcranial direct current stimulation | SEP | NA | NCT02538094 | tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis | COMPLETED |
| Psilocybin | Sclérose latérale amyotrophique | Phase 1 | NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | RECRUITING |
Publications
28| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | The effect of anti-seizure medications on lipid values in adults with epilepsy. | Epilepsy & behavior : E&B | ||
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | Impact of low-carbohydrate diet on health status: an umbrella review. | Frontiers in nutrition | ||
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | Carotid intima-media thickness may be an early biomarker for cardiovascular risk in patients treated with ketogenic dietary therapy. | Epilepsia open | ||
| [11C]CPPC PET ligand | PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). | Proceedings of the National Academy of Sciences of the United States of America | ||
| embolization of middle meningeal arteries | Middle Meningeal Artery Embolization With n-Butyl Cyanoacrylate in Patients With Chronic Subdural Hematoma: A Randomized Clinical Trial. | JAMA neurology | ||
| Migraine and Body Composition | Examining the molecular mechanisms of topiramate in alleviating insulin resistance: A study on C2C12 myocytes and 3T3L-1 adipocytes. | Endocrine | ||
| INTENT Neural Interface System | Integrating large language models into Peer-to-Peer energy management for multi-tenant buildings: A guardrail approach to ensuring resilience. | Neural networks : the official journal of the International Neural Network Society | ||
| INTENT Neural Interface System | Technologies in clinical neurophysiology for brain-body interfacing: IFCN handbook chapter. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology | ||
| INTENT Neural Interface System | HADANet: hybrid attentive domain adaptation for cross-subject motor imagery EEG decoding. | Cognitive neurodynamics | ||
| Belimumab | Factors Associated with Glucocorticoid Withdrawal in Systemic Lupus Erythematosus: A Multicentre ANSWER-SLE Cohort. | Modern rheumatology | ||
| Belimumab | Pediatric Systemic Lupus Erythematosus Complicated by Acute EBV and CMV Co-infection. | Journal of clinical laboratory analysis | ||
| LINKED-BP — Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure | Design and Rationale of the Home Blood Pressure Telemonitoring Linked with Community Health Workers to Improve Blood Pressure (LINKED-BP) Program. | American journal of hypertension | ||
| Team-based shared decision-making | Interprofessional education in pharmacy: Bridging collaborative competence and clinical impact. | Currents in pharmacy teaching & learning | ||
| Team-based shared decision-making | Exploring Interprofessional Primary Care (IPPC) teams' impact on chronic disease management: a narrative review on guiding features and reported outcomes. | Journal of interprofessional care | ||
| Team-based shared decision-making | Rethinking obesity management targets: Findings from an international MoSCoW prioritization workshop. | Obesity pillars | ||
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. | Contemporary clinical trials | ||
| Belimumab | Voclosporin for the treatment of lupus nephritis flares in patients with inadequate response to mycophenolate mofetil and belimumab: a case series. | Journal of nephrology | ||
| Migraine and Body Composition | Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years. | The Cochrane database of systematic reviews | ||
| Migraine and Body Composition | Metabolic, adherence, and sustainability outcomes of plant-based low-carbohydrate and ketogenic diets: A systematic review of clinical evidence. | Nutrition (Burbank, Los Angeles County, Calif.) | ||
| Anodal Transcranial direct current stimulation | The Impact of Anodal tDCS on Verbal and Nonverbal Functional Communication in Subacute Aphasia-An Observational Study. | Brain sciences | ||
| Anodal Transcranial direct current stimulation | Long-Lasting Changes of Repeated Anodal Transcranial Direct Current Stimulation in Decreasing Chronic Pain in Patients with Multiple Sclerosis: A Case Series. | Brain sciences | ||
| Anodal Transcranial direct current stimulation | Prefrontal transcranial direct current stimulation in alcohol use disorder: a pilot randomized sham-controlled trial with exploratory effects on reward craving and depressive symptoms. | Addictive behaviors | ||
| Anodal Transcranial direct current stimulation | Increased brain glucose metabolism after anodal left DLPFC-right shoulder tDCS in ASD: an open-label pilot F-18 FDG PET/CT study. | BMC psychiatry | ||
| Anodal Transcranial direct current stimulation | Training-induced cognitive coupling emerges under sham but not active transcranial electrical stimulation in older adults: a triple-blind, randomized, sham-controlled study. | Journal of neuroengineering and rehabilitation | ||
| Anodal Transcranial direct current stimulation | Heterogeneous Recruitment Curve Responses to Anodal Transcranial Direct Current Stimulation in Children With Unilateral Spastic Cerebral Palsy. | Neurorehabilitation and neural repair | ||
| Anodal Transcranial direct current stimulation | Does Anodal Transcranial Direct Current Stimulation Over the Primary Motor Cortex Really Enhance Motor Sequence Learning? | Biological psychiatry global open science | ||
| Anodal Transcranial direct current stimulation | Effects of transcranial electric stimulation on attentional functions in healthy adults: A meta-analysis. | Biological psychology | ||
| Anodal Transcranial direct current stimulation | Concurrent effects of EMG-triggered NMES and anodal tDCS on cortical and behavioural outcome measures: The role of ipsilateral versus contralateral anodal stimulation. | Brain research |